A Randomised, Double-Blind, Placebo-Controlled 6-month Study to Evaluate the Efficacy, Safety, and Tolerability of Sarizotan in Patients With Rett Syndrome With Respiratory Symptoms
Phase of Trial: Phase II/III
Latest Information Update: 16 Nov 2017
At a glance
- Drugs Sarizotan (Primary)
- Indications Rett syndrome
- Focus Registrational; Therapeutic Use
- Acronyms STARS
- Sponsors Newron Pharmaceuticals
- 25 Oct 2017 According to a Newron Pharmaceuticals media release, this study will be presented at European Rett Syndrome Congress November 2017.
- 14 Sep 2017 Newron is working towards completion of recruitment by the end of 2017, according to a company media release.
- 23 Jun 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2018.